Market Overview:
The global metastatic bone disease treatment market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of cancer, increasing awareness about metastatic bone disease treatment options, and technological advancements in the field of metastatic bone disease treatment. However, the high cost of treatments and lack of reimbursement policies are restraining the growth of this market. The global metastatic bone disease treatment market is segmented on the basis of type, application, and region. On the basis of type, it is divided into medication, radiation therapy, surgical intervention, and tumor ablation therapy. On the basis on application it is classified into hospitals, specialty clinics ambulatory surgical centers). Geographically it covers North America (U.S., Canada), Latin America (Mexico), Europe (Germany France Italy Spain U K), Asia Pacific (Japan China India Australia South Korea) Middle East & Africa(South Africa Saudi Arabia UAE).
Product Definition:
Metastatic bone disease is a cancer that has spread from one part of the body to another, most often affecting the bones. Treatment for metastatic bone disease may include chemotherapy, radiation therapy, or surgery. The goal of treatment is to control the cancer and relieve symptoms.
Medication:
Metastatic bone disease is a progressive disorder of bones that occurs after the removal of cancerous tumors. The most common types are osteosarcoma and Ewing's tumor.
Osteosarcoma Treatment Market By Region (USD Million), 2018 - 2025 -> The global medication, its usage & growth factor in metastatic bone disease treatment market size was valued at USD 1,26 billion in 2016.
Radiation Therapy:
Radiation therapy is a form of treatment used to control and/or eliminate cancerous cells from the body. Radiation oncology is a branch of medical oncology which deals with the study, prevention, diagnosis, and treatment of cancer caused due to radiation.
Application Insights:
The hospitals segment dominated the market in 2017 and is expected to maintain its dominance over the forecast period. This can be attributed to factors such as presence of a large patient base suffering from metastatic bone disease, increasing number of hospital-based research studies on various treatment options, and availability of advanced healthcare facilities.
Specialty clinics are anticipated to witness lucrative growth over the forecast period owing to rising awareness about available treatment options for metastatic bone disease coupled with growing preference for outpatient procedures. Furthermore, increasing government funding for cancer care along with an increase in patients seeking second opinions regarding their condition are some other factors driving specialty clinic expansion projects across the globe Metastatic bone diseases affect people irrespective of their age or sex; thus resulting in increased incidence among males as compared to females.
Regional Analysis:
North America accounted for the largest revenue share in 2017. The region is expected to maintain its lead throughout the forecast period owing to favorable reimbursement policies, increasing R&D investments by industry players and government initiatives. For instance, in May 2018, Pfizer Inc., a U.S.-based pharmaceutical company announced about funding of USD X million over three years for research on immunotherapies as primary treatment option for patients with metastatic bone disease who have progressed following initial therapy with anti-PDL1 or PD-1 immune checkpoint inhibitors (ICIs).
Asia Pacific is estimated to be the fastest growing regional market during the forecast period due to rising healthcare expenditure and improving economic conditions in emerging countries such as China & India & South Korea etcetera – all these factors are anticipated to boost demand over next eight years.
Growth Factors:
- Increasing incidence of metastatic bone disease
- Growing awareness about metastatic bone disease and its treatment options
- Rising demand for better and more effective treatments for metastatic bone disease
- Technological advancements in the field of metastatic bone disease treatment
- Growing number of clinical trials for new and innovative therapies for metastatic bone disease
Scope Of The Report
Report Attributes
Report Details
Report Title
Metastatic Bone Disease Treatment Market Research Report
By Type
Medication, Radiation Therapy, Surgical Intervention, Tumor Ablation Therapy
By Application
Hospitals, Specialty Clinics, Ambulatory Surgical Centers
By Companies
Merck & Co., Eli Lilly and Company, F. Hoffmann-La Roche, Amgen, Novartis, Bayer, BTG, Fresenius Kabi, Medtronic, Boston Scientific Corporation
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
176
Number of Tables & Figures
124
Customization Available
Yes, the report can be customized as per your need.
Global Metastatic Bone Disease Treatment Market Report Segments:
The global Metastatic Bone Disease Treatment market is segmented on the basis of:
Types
Medication, Radiation Therapy, Surgical Intervention, Tumor Ablation Therapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Specialty Clinics, Ambulatory Surgical Centers
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck & Co.
- Eli Lilly and Company
- F. Hoffmann-La Roche
- Amgen
- Novartis
- Bayer
- BTG
- Fresenius Kabi
- Medtronic
- Boston Scientific Corporation
Highlights of The Metastatic Bone Disease Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Medication
- Radiation Therapy
- Surgical Intervention
- Tumor Ablation Therapy
- By Application:
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Metastatic Bone Disease Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Metastatic bone disease treatment is a combination of medications and surgery that aim to slow or stop the spread of cancer cells to other parts of the body. Treatment may include chemotherapy, radiation therapy, and surgery.
Some of the major companies in the metastatic bone disease treatment market are Merck & Co., Eli Lilly and Company, F. Hoffmann-La Roche, Amgen, Novartis, Bayer, BTG, Fresenius Kabi, Medtronic, Boston Scientific Corporation.
The metastatic bone disease treatment market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Metastatic Bone Disease Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Metastatic Bone Disease Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Metastatic Bone Disease Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Metastatic Bone Disease Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Metastatic Bone Disease Treatment Market Size & Forecast, 2018-2028
4.5.1 Metastatic Bone Disease Treatment Market Size and Y-o-Y Growth
4.5.2 Metastatic Bone Disease Treatment Market Absolute $ Opportunity
Chapter 5 Global Metastatic Bone Disease Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Metastatic Bone Disease Treatment Market Size Forecast by Type
5.2.1 Medication
5.2.2 Radiation Therapy
5.2.3 Surgical Intervention
5.2.4 Tumor Ablation Therapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Metastatic Bone Disease Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Metastatic Bone Disease Treatment Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Specialty Clinics
6.2.3 Ambulatory Surgical Centers
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Metastatic Bone Disease Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Metastatic Bone Disease Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Metastatic Bone Disease Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Metastatic Bone Disease Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Metastatic Bone Disease Treatment Market Size Forecast by Type
9.6.1 Medication
9.6.2 Radiation Therapy
9.6.3 Surgical Intervention
9.6.4 Tumor Ablation Therapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Metastatic Bone Disease Treatment Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Specialty Clinics
9.10.3 Ambulatory Surgical Centers
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Metastatic Bone Disease Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Metastatic Bone Disease Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Metastatic Bone Disease Treatment Market Size Forecast by Type
10.6.1 Medication
10.6.2 Radiation Therapy
10.6.3 Surgical Intervention
10.6.4 Tumor Ablation Therapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Metastatic Bone Disease Treatment Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Specialty Clinics
10.10.3 Ambulatory Surgical Centers
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Metastatic Bone Disease Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Metastatic Bone Disease Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Metastatic Bone Disease Treatment Market Size Forecast by Type
11.6.1 Medication
11.6.2 Radiation Therapy
11.6.3 Surgical Intervention
11.6.4 Tumor Ablation Therapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Metastatic Bone Disease Treatment Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Specialty Clinics
11.10.3 Ambulatory Surgical Centers
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Metastatic Bone Disease Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Metastatic Bone Disease Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Metastatic Bone Disease Treatment Market Size Forecast by Type
12.6.1 Medication
12.6.2 Radiation Therapy
12.6.3 Surgical Intervention
12.6.4 Tumor Ablation Therapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Metastatic Bone Disease Treatment Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Specialty Clinics
12.10.3 Ambulatory Surgical Centers
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Metastatic Bone Disease Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Metastatic Bone Disease Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Metastatic Bone Disease Treatment Market Size Forecast by Type
13.6.1 Medication
13.6.2 Radiation Therapy
13.6.3 Surgical Intervention
13.6.4 Tumor Ablation Therapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Metastatic Bone Disease Treatment Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Specialty Clinics
13.10.3 Ambulatory Surgical Centers
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Metastatic Bone Disease Treatment Market: Competitive Dashboard
14.2 Global Metastatic Bone Disease Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Merck & Co.
14.3.2 Eli Lilly and Company
14.3.3 F. Hoffmann-La Roche
14.3.4 Amgen
14.3.5 Novartis
14.3.6 Bayer
14.3.7 BTG
14.3.8 Fresenius Kabi
14.3.9 Medtronic
14.3.10 Boston Scientific Corporation
